RESEARCH DOSSIER
Preventive Care Incentives and Health Insurance Benefit Design
Abstract. Preventive services occupy a distinctive position within health insurance because current coverage terms can alter the future distribution of disease, disability, treatment intensity, insurer claims, household spending, and population health. Their benefit design joins clinical eligibility, contract pricing, patient and provider behavior, program organization, intertemporal finance, and distributional justice. This monograph investigates preventive screening, immunization, cessation, and risk-reducing treatment through international evidence and established causal and welfare-economic methods. It differentiates the effect of a benefit on service take-up from the effect of service use on health, and the subsequent effect of health change on insurer and social costs. It synthesizes randomized health insurance experiments, targeted reward trials, disease-management and deductible studies, economic projections, official clinical and public health guidance, comparative screening programs, and preventive coverage law. First-dollar coverage can increase the use of valuable services where direct payment constrains access; cash rewards have demonstrable effects in some settings, especially smoking cessation, but produce modest or null responses in some colorectal-screening designs. Increased preventive claims do not establish improved clinical outcomes, and reduced aggregate claims do not establish either improved health or social savings. The comparative synthesis finds that the effective patient price includes administrative and time costs; that diagnostic follow-up and provider capacity condition the value of screening; that enrollment turnover changes the private insurer's incentive to finance prevention; and that economic evaluations must declare the population, comparator, horizon, discounting, harms, and payer perspective. These are evidence-grounded analytical findings derived from existing scientific frameworks. The monograph advances no new doctrine, proprietary model, universal return estimate, or clinical guideline.
Keywords: Health insurance; preventive care; preventive benefits; screening; immunization; financial incentives; cost sharing; deductible exemptions; first-dollar coverage; risk reduction; provider incentives; behavioral hazard; service uptake; causal inference; financial protection; cost offsets; cost-effectiveness; social welfare; health equity; international health systems.
Introduction
Health insurance is an institution for distributing the financial consequences of uncertain illness. Preventive care modifies that institution's relationship with the events being insured. A benefit can change whether a person receives a vaccine before exposure, undertakes screening before symptoms develop, quits smoking, or continues evidence-based medicines after an earlier cardiac event. The immediate covered claim may increase because an intervention occurs, while the future distribution of disease and care changes in ways that require separate observation and identification.
Three questions govern scientific evaluation. Does a benefit change participation in a clinically indicated preventive service? Does that intervention improve patient-important health outcomes once harms and completion of the care pathway are taken into account? Does the resulting outcome alter spending by an insurer, household, health system, or society over a declared horizon? These questions have different dependent variables, mechanisms, and appropriate evidence. The answer to the first does not logically establish the second or third.
The RAND randomized insurance experiment showed that general use of medical care responds to out-of-pocket price (Manning et al. 1987). The Oregon insurance lottery demonstrated increased health care utilization and financial protection among those receiving Medicaid through a randomized opportunity to apply (Finkelstein et al. 2012). Both are foundational to understanding insurance, but neither alone identifies the optimal price of every preventive service. Disease-specific clinical effectiveness, population eligibility, provider capacity, patient time, and the meaning of the counterfactual must enter the evaluation.
A national coverage entitlement also differs from an operating program. The right to a screening test can coexist with limited appointments, travel costs, diagnostic delays, ambiguous coding, and incomplete follow-up. The WHO screening program guide stresses the importance of program quality and the steps following a test (WHO Regional Office for Europe 2020). Preventive benefit design therefore connects statutory rights, clinical evidence, insurance contracts, behavior, and delivery infrastructure.
This Research Dossier is situated principally within Health Insurance and is related to Insurance Economics and Risk Engineering and Loss Prevention. The scope encompasses insurance-financed screening, immunization, risk reduction, and recurrence prevention. It examines primary studies and institutional documents, compares research designs, and derives source-grounded conclusions without reanalyzing individual-level datasets or constructing a universal quantitative estimate.
Scientific Foundations and Historical Development
The intervention, risk, and temporal dimensions of prevention
Primary prevention aims to avert disease or injury before its onset. Vaccination and smoking cessation are examples when applied to susceptible people without the outcome being prevented. Secondary prevention includes earlier identification of disease through suitable screening and prevention of recurrent events after a first clinical episode. Tertiary prevention seeks to limit complications and functional deterioration in established disease. Their boundaries depend on the outcome chosen: following myocardial infarction, a drug may be secondary prevention of another infarction while forming part of treatment for the underlying chronic condition.
These purposes require different methods. A vaccine's benefit may depend on baseline incidence, direct biological protection, duration, and indirect transmission effects. Screening depends on the test's sensitivity and specificity, the interval, the risk profile, timely confirmation and successful treatment. Preventive medication depends on persistence, correct use, clinical risk, and adverse effects. Health insurance cannot assume the same marginal effect of removing a copayment for all three.
Time is decisive. Preventive expenditure appears at service delivery; averted costs can occur after months, years, or decades. The payer making an initial investment may cease to cover the patient before the benefit emerges. An insurer facing annual enrollment changes may rationally view the same intervention differently from a tax-financed system covering a population over many years. This is an institutional horizon problem derived from ordinary present-value and incidence analysis, not a newly devised economic principle.
The distinction between prevention and detection also matters. Detecting an otherwise unrecognized condition changes its recorded prevalence immediately, even if the future health effect is uncertain. This accounting effect can raise diagnosed morbidity while making access to subsequent treatment better. A program's success cannot be inferred solely from more tests or more diagnosed cases.
Historical integration of insurance and public health
Insurance originally developed around pooling and paying for realized losses, whereas population-level infectious-disease control and screening have often relied on public institutions. Contemporary health systems integrate private and social insurance, tax-funded prevention, clinical guideline bodies, and organized screening. Their financing categories remain different, but the same intervention may be publicly recommended, privately reimbursed, and delivered by an independent clinician.
The development of clinical evidence assessment transformed eligibility from a generic list of tests into a judgment about the net effects of a specific service in a specific population. The USPSTF recommendation procedure distinguishes magnitude of benefit, harms, and certainty. This offers a disciplined basis for benefit decisions, although clinical recommendations and legal coverage obligations remain institutionally separate.
The 2022 EU screening recommendation illustrates an organized approach centered on target populations, evidence, monitoring, and quality assurance rather than a uniform private-insurance claims rule. Australia supplies another form, combining publicly financed home screening kits and scheduled invitations with other Medicare rules. These historical variations demonstrate that preventive finance has developed through multiple institutions rather than through a single standard insurance mechanism.
Research method and inference hierarchy
The primary analytical method is critical comparison of experiments, quasi-experiments, observational studies, official legal material, systematic reviews, and decision-analytic projections. An experiment can estimate the causal effect of the offer or assignment under its actual implementation. If compliance differs between treatment and control, the effect of receiving the intervention requires additional assumptions. Observational comparisons can document important associations, but their causal interpretation depends on selection, measured confounding, time-varying changes, and the credibility of controls.
Clinical evidence answers whether a service has net benefit under defined indications. Insurance evidence answers whether benefit design changes access or behavior. Economic evaluation answers how benefits and costs are allocated over time. The source types are complementary; none can stand in for another. A model of projected lifetime cost-effectiveness should never be described as direct observation of lifetime outcomes from a short trial.
The present synthesis gives preference to primary studies for quantitative claims and primary institutional texts for law and program eligibility. A systematic review is used to evaluate the consistency of an intervention-specific trial literature. No statistical pooling across interventions is undertaken because the clinical behaviors, treatment definitions, comparators, populations, and horizons differ substantially.
Preventive Benefit Eligibility and Contractual Design
Eligibility as a multi-stage relation
Preventive benefit eligibility combines a person's coverage class, clinical indication, legal and contractual terms, service network, effective date, and the administrative definition of the intervention. A clinical recommendation for an age- and risk-defined group does not make every enrolled person eligible for every version of the service. A zero-copayment commitment may depend on using a suitable provider, following evidence-based intervals, or distinguishing screening from diagnostic care.
Insurance evaluation should record the relevant person-year, plan contract, date of recommendation, eligibility criteria, screening modality, frequency, and administrative code. The absence of a claim may reflect a rational decision, a missed invitation, a different payer, a test performed outside the insurer's record, or a supply shortage. The presence of a claim may reflect repeat testing, conversion to diagnostic care, or better capture of a previously invisible service.
A care pathway begins before the billable event. Awareness, trust, scheduling, transport, preparation, and prior authorization if applicable determine practical access. It continues after the event: abnormal results must be communicated and evaluated; disease may require treatment, surveillance, and adherence. Covering the first step without ensuring a feasible second step can increase recorded participation while reducing the fraction of positive results appropriately resolved.
U.S. recommended preventive coverage
The American statutory framework offers a particularly explicit link between evidence review and health insurance benefits. Under 42 U.S.C. § 300gg–13, qualifying group and individual health plans are generally required to cover specified preventive services without patient cost sharing, subject to the statutory framework and exceptions. Covered categories include certain recommendations with USPSTF grades A or B, immunizations under the relevant committee recommendations, and HRSA-supported services. Actual obligations depend on plan type, implementation rules, timing, and clinical indication. The text does not establish a universal zero price for every health-related checkup or every downstream diagnostic treatment.
The implementation rules make the boundary concrete. In the ACA preventive-services FAQs, federal agencies addressed such issues as polyp removal integral to a screening colonoscopy and the circumstances under which an otherwise recommended service must be available outside the network without cost sharing. The patient's price depends on coding, network access, and the covered clinical pathway as well as on the advertised benefit category.
A relevant constitutional question was resolved in the U.S. Supreme Court's Kennedy v. Braidwood decision on June 27, 2025. The Court held that members of the Preventive Services Task Force were inferior officers whose appointment by the Secretary of Health and Human Services satisfied the Appointments Clause. This holding addressed the legal appointment issue before the Court. It did not perform a new clinical assessment of each screening recommendation or determine future updates to the prevention benefit schedule.
A researcher comparing claims before and after a coverage rule must preserve legal version, service code, plan exemption status, network rules, and implementation date. Apparent growth in 'preventive care' could result partly from new billing or payer classification. A meaningful utilization estimate requires harmonized service definitions and, where possible, independent confirmation of the intervention actually received.
European organized screening and Australia
The EU Council screening recommendation guides Member States toward evidence-based, quality-assured organized cancer screening. It is a recommendation in a multinational policy architecture, and national eligibility, invitations, insurance entitlements, provider contracts, and implementation dates vary. A cross-country comparison must distinguish adherence to common program goals from the legal form of a particular nation's benefit.
Australia's Medicare screening arrangements include national bowel, cervical, and breast screening schemes. Free home bowel screening kits, invitation and recall mechanisms, and nationally administered eligibility can reduce both financial and logistical burdens. From July 2024, the National Bowel Cancer Screening Program expanded access for ages 45–49, with age-dependent invitation and ordering arrangements. Such details are tied to the actual program year and should never be generalized as global clinical advice.
The comparative insight is that equal nominal prices do not imply equal realized access. A national home-test invitation may overcome informational and scheduling barriers that a clinic-based insurance benefit leaves intact. Conversely, a publicly supplied test may still require follow-up in a separate clinical or financing pathway. Country effects must be understood through invitation systems, diagnostic capacity, data registry completeness, and risk profiles.
Effective patient price and benefit design variables
The patient faces more than a copayment. A useful accounting description of effective burden is monetary payment plus time, transport, foregone earnings, caregiving, administrative effort, and uncertainty about subsequent charges. These components are not commensurable as observed cash expenses without a valuation method; their identification matters even when no combined numerical price is calculated.
Zero-cost sharing can lower the first component but leave the others high. Financial rewards can offset some monetary and effort costs, yet may be irrelevant when appointments are unavailable. A mailed test changes both the form of service and its practical burden. Provider-initiated scheduling can reduce information and transaction costs. A scientific evaluation therefore specifies the exact intervention as the patient experiences it, rather than merely coding a binary insurance benefit flag.
Benefit designers must also distinguish financial design from medical management. Appropriate age limits, risk eligibility, service intervals, and contraindications protect against low-value use; opaque documentation and overly restrictive administrative steps can block high-value care. The design question is whether the total arrangement delivers indicated services with defensible resource use and clear patient financial exposure.
Take-Up, Substitution, and Incentive Evidence
Insurance prices and behavioral mechanisms
Insurance changes how costs are borne. Lower cost sharing generally reduces the monetary price at the point of service, but the resulting use can be clinically valuable, low value, or harmful depending on the intervention and patient. Baicker, Mullainathan, and Schwartzstein (2015) explain that behavioral frictions and mistakes can produce underuse of high-value health care even where traditional price-based analysis predicts greater use. The marginal value of use induced by a benefit matters more than the raw utilization count.
Four incentive channels are analytically relevant. The price channel operates through payment at service. The reward channel adds a positive contingent payoff for verified behavior. The information channel changes awareness, salience, and expectations. The supply channel changes a provider's willingness or ability to offer, organize, or complete services. A policy may combine these channels; an evaluation of a combined intervention must identify the treatment bundle.
Rewards also introduce inframarginal expenditure. When a benefit pays people who would have completed a service without the incentive, reward payouts rise even if marginal uptake changes little. Whether a reward is cost-effective depends on induced behavior, administrative costs, subsequent outcomes, and targeting. A positive association between rewards paid and screenings completed is insufficient because the former may follow the latter without causing the additional uptake.
Broad insurance experiments: RAND and Oregon
The landmark RAND randomized evidence established responsiveness of medical demand to cost sharing (Manning et al. 1987). The study compared randomized insurance terms, not a single universally recommended preventive service. In its studied setting, lower outpatient use from cost sharing did not generate a broad compensating hospitalization increase. This limits the claim that every reduction in outpatient care inevitably raises near-term total expenditure, but it cannot rule out longer-term prevention benefits for specific interventions.
The Oregon first-year analysis exploits a randomized lottery determining an opportunity to apply for Medicaid (Finkelstein et al. 2012). Insurance access increased the use of care and produced important financial protection. The lottery assignment identifies an offer effect; estimates of enrollment-related effects require assumptions about compliance and exclusion. Oregon therefore informs the effect of broader insurance coverage under a particular state program, not merely the removal of one screening copayment.
The subsequent two-year Oregon clinical study found greater preventive service use, diabetes diagnosis, and medication use, and a lower probability of a positive depression screen; several measured physical outcomes did not show statistically significant improvement over the study horizon (Baicker et al. 2013). The positive-depression-screen effect was approximately 9.15 percentage points lower, with a 95% confidence interval of −16.70 to −1.60 percentage points. A nonsignificant physical outcome indicates that the study did not establish a difference of the required precision for that endpoint. It is neither proof that the true effect is zero nor proof that the preventive increase improved every dimension of physical health.
The combined inference is that coverage expansions can produce measurable access and utilization effects without yielding definitive clinical evidence for every measured condition within two years. Treating a process endpoint as a mortality endpoint would overstate the experiment; disregarding changes in financial protection because a physical biomarker lacked statistical significance would ignore an outcome the experiment actually established.
Targeted screening cost-sharing evidence
The analysis of Medicare managed-care plans by Trivedi, Rakowski, and Ayanian (2008) found biennial mammography screening rates about 8.3 percentage points lower in plans imposing cost sharing than in plans offering full coverage. Differences were larger in places with lower household income and education. The study additionally examined changes after introduction of cost sharing, strengthening the behavioral interpretation, but assignment to all relevant plan and patient circumstances was observational.
This distinction matters for attribution. A lower screening rate in a cost-sharing plan may reflect the patient price, plan selection, provider practices, or differences not fully captured by controls. The evidence nevertheless shows a meaningful price-related barrier in the Medicare settings studied. It also indicates why removing nominal copayments can improve distributional access even when a universal average effect cannot be claimed.
Cancer screening is an especially demanding evaluation case. A covered screening test is an entry point to a sequence of result notification, diagnosis, possible treatment, and surveillance. Changes in initial use do not quantify averted mortality without further evidence. A benefit can lower immediate patient expenses while shifting costs to the insurer and increasing needed diagnostic work; neither effect is automatically a social loss.
Medication adherence as recurrent-event prevention
For patients with established chronic disease, the insurer may finance effective medication to prevent serious exacerbations or recurrent events. The observational employer-based Chernew et al. (2008) intervention combined reduced copayments with a disease-management context and found improvements in adherence for four of five medication classes. The reported nonadherence reductions were approximately 7–14 percent in the intervention comparison. Because the program was not individually randomized, the findings should be interpreted within employer and concurrent-program conditions.
A more rigorous targeted trial is MI FREEE, which randomized plan sponsors to full coverage or usual coverage of evidence-based medicines following myocardial infarction (Choudhry et al. 2011). Medication adherence increased by roughly four to six percentage points. Its prespecified primary composite event rate was 17.6 versus 18.8 per 100 person-years, hazard ratio 0.93, 95% confidence interval 0.82–1.04, and did not achieve statistical significance. Selected secondary cardiovascular endpoints improved; patients paid less out of pocket, and measured total spending did not significantly increase.
These details constrain the interpretation. Full drug coverage demonstrably increased adherence; the trial's primary health event composite was not conclusively improved. Secondary effects and patient financial protection still matter. Claims for prescriptions are also an imperfect proxy for actual consumption, correct dose, drug persistence, and clinical benefit. A benefit should be assessed alongside care transition, pharmacy access, prescriber continuity, and risk-appropriate treatment.
Financial rewards and smoking cessation
Direct monetary incentives change the private payoff from a verified preventive action. A randomized cessation trial among employees found prolonged smoking abstinence of 14.7% under an incentive package versus 5.0% under the control arrangement at its principal follow-up (Volpp et al. 2009). The intervention included a structured reward schedule and biochemical verification. It estimates an effect in that employment and incentive context, and not an effect of all possible premium discounts.
The updated Cochrane cessation evidence (Notley et al. 2025) supports a sustained effect of incentives on quitting at six months or longer. In the review's mixed-population analysis, the pooled risk ratio was 1.52, with 95% confidence interval 1.33–1.74 across 39 studies including 18,303 participants. Evidence was rated high certainty for that outcome. Differences in incentive magnitude, setting, and delivery prevent the pooled effect from becoming a guaranteed rate of success under a particular insurance contract.
There is a behavioral mechanism behind reward effectiveness, but the mechanism does not render all incentives substitutable. Smoking cessation is a repeated behavioral process with objectively verifiable endpoints; a once-only screening appointment differs in perceived value, frequency, effort, and clinical risk. Performance payments that work in one behavior may perform differently when a condition is scarce, verification is difficult, or the baseline program already reduces barriers.
Colorectal-screening rewards: positive and null trials
The contrast between two randomized colorectal studies demonstrates heterogeneity. In an employee colonoscopy experiment, a $100 financial incentive increased completion over three months to 3.7%, compared with 1.6% under standard email and 1.5% under active-choice email (Mehta et al. 2017). The absolute effect was small despite a detectable increase. The specific task was colonoscopy and the population consisted of employees eligible for screening.
A subsequent mailed fecal immunochemical test experiment found that small cash and lottery rewards did not significantly improve completion compared with mailed testing alone (Mehta et al. 2019). The respective two-month completion rates were 26.0% for the no-reward group and 27.2%, 23.2%, and 17.7% under three reward designs, with expected reward values around $10. Mailing a test to all groups was already a strong baseline intervention; additional payment did not show reliable incremental effectiveness under the trial conditions.
The two trials cannot isolate incentive amount as the sole explanation for their different results. They also differed in modality, burden, participant population, baseline outreach, measurement window, and verification. Their joint result is precise: inducement effects depend on the entire intervention and context. Reward size should be tested rather than assumed, and control-group behavior must be reported.
Substitution, spillovers, and provider response
When a benefit becomes more generous, patients can move an intervention from out-of-pocket financing to insurance claims without increasing total preventive care. They may switch from one screening modality to another, from a public to a private provider, or from lower-intensity to higher-intensity services. Preventive care may avert future acute care; this last form of substitution has a later outcome and must be independently estimated. All can change recorded insurer expenditure, but their welfare implications differ.
Provider response also matters. Clinicians choose whom to invite, explain tests, administer interventions, and arrange follow-up. If a contract increases demand without expanding capacity, waiting lists may lengthen or resources may shift from other services. A financial incentive targeted at a measurable screening rate can increase testing without equally improving diagnostic completion. The high-deductible employer evidence of Brot-Goldberg et al. (2017) illustrates that health care use can respond to cost sharing through quantity reductions rather than efficient shopping for lower prices.
A rigorous study must distinguish true incident prevention from changes in claims ascertainment. It should also detect spillovers: an employer's incentive program can affect clinicians who treat control-group employees, and a population vaccination program may change exposure risk among nonparticipants. Depending on the intervention, conventional no-interference assumptions may be unrealistic.
Health Outcomes, Economic Valuation, and Cost Offsets
Process results and patient-important outcomes
A completed test, a recorded vaccine, an appointment, or a filled prescription is a process outcome. It provides evidence of access and service use but carries different implications for clinical value. Screening can detect abnormalities early and prompt effective treatment; it can also generate false positives, incidental findings, unnecessary procedures, and anxiety. Earlier recorded diagnosis may increase measured survival from diagnosis without changing the time of death, a lead-time effect.
The WHO cancer screening guide emphasizes balancing effectiveness against harms and implementing the entire screening pathway. Some forms of screening may reduce disease incidence by identifying treatable precursors, whereas others principally aim to reduce mortality through earlier effective treatment. The endpoint must match the causal purpose. A high test positivity rate is not necessarily a high program-benefit rate.
The USPSTF net-benefit methods integrate benefit, harm, and certainty in clinical recommendations. Insurance administrators should preserve these distinctions when translating guidance into benefit eligibility. Clinical evidence should determine where screening is indicated, and local delivery data should determine whether the pathway can be completed safely.
Payer spending, household protection, and social resources
A claim paid by an insurer, an out-of-pocket bill, and a unit of real health-system resource use are distinct economic quantities. A cost-sharing increase can reduce the insurer's paid claims partly by shifting expense to patients. A more generous preventive benefit can increase insurer payments while reducing household hardship. Neither change alone measures the total resource cost of care.
For a common insured population and horizon T, an accounting representation of the insurer's incremental cost is:
ΔC_payer(T) = ΔC_prevention(T) + ΔC_administration(T) + ΔC_rewards(T) + ΔC_downstream(T).
The change in downstream care is defined relative to the same counterfactual and may have either sign. Costs should be discounted when the horizon and conventions require, and adjusted for membership exits, deaths, differing prices, and risk mix. This identity names components of established budget-impact accounting. It is not an original predictive model. The result may be negative, indicating a payer offset, even if health outcomes are unchanged; it may be positive despite substantial patient benefit.
Social evaluation counts resources used and health gained or lost across parties, while avoiding double-counting financing transfers. A household's medical bill can create financial hardship even where the payer's actuarial accounting records the same service differently. The WHO account of universal health coverage recognizes both service access and protection from financial hardship. An evaluation restricted to claims savings misses those dimensions.
Why prevention need not save money
A clinically valuable preventive service can be cost-increasing. It has immediate delivery and implementation costs, may extend life into years requiring other care, and may yield gains expressed primarily in quality and longevity rather than avoided expenditure. Conversely, low-value screening can incur both direct costs and downstream harms. Cohen, Neumann, and Weinstein (2008) make the central economic distinction: saving money and producing health benefits at an acceptable incremental cost are different propositions.
The correct perspective is specified before the calculation. A private insurer may have a limited membership horizon and incomplete access to future benefits. A national system may finance interventions and downstream treatment for many years, yet still face separate appropriations and opportunity costs. A patient may benefit from averted illness regardless of the insurer's ability to capture fiscal returns. Reporting 'the savings of prevention' without specifying the beneficiary of those savings is scientifically incomplete.
A further distinction separates budget impact from cost-effectiveness. The former asks whether a payer can finance a program and what its cash outlays become; the latter asks what resources are spent for additional health. A program may have favorable long-run cost-effectiveness while imposing large near-term costs on a fiscally constrained health system. This does not invalidate either calculation. It means they answer different questions.
Direct observation and projection
The randomized MI FREEE evidence provides observed adherence, event, and payment results over its study follow-up. A later long-term economic projection by Ito and colleagues (2015) used a decision model informed by trial and literature inputs. It estimated approximately 0.14 additional quality-adjusted life years and about $4,011 lower resource use per person for full medication coverage under its assumptions. Those are modeled lifetime results, not directly observed lifetime reductions in the original randomized trial.
Model credibility depends on risk persistence, treatment effectiveness, event costs, competing mortality, treatment switching, drug use, and discounting. Small parameter changes can matter substantially when benefits accrue years after the intervention. A model must reveal sensitivity and distinguish measured treatment effects from transported estimates and expert assumptions.
Population-level ranking is another established economic tool. The preventive-service priority assessment by Maciosek et al. (2017) compared evidence-based services by potential health impact and cost-effectiveness, explicitly recognizing finite implementation resources. The existence of many clinically beneficial interventions does not remove the need to prioritize services with regard to avoidable disease, access, and resources consumed.
Diagnostic workload, unintended effects, and clinical governance
Screening raises the probability that a finding needs diagnostic follow-up. A positive test may require another test, a biopsy, treatment, or surveillance. A payer counting only first-stage screening may show a rapid uptake gain while missing harm from false positives or failure to complete follow-up. The WHO screening program framework treats organized monitoring, quality control, and subsequent clinical capacity as essential components of a credible program.
The economic effect depends on how many additional tests reach people with meaningful underlying risk, how accurate testing is, and what happens after positive results. A higher number of cancers detected can reflect earlier useful identification, overdiagnosis, changed ascertainment, or a combination. Distinguishing these possibilities requires appropriate endpoints, follow-up, and clinical evidence beyond a claim count.
For immunization, the expected benefit depends on intervention-specific effectiveness, disease incidence, program completion, population mixing, and possible indirect protection. There is no defensible generic fiscal multiplier applying to all vaccinations and countries. The present dossier therefore does not supply an invented universal vaccine return or extrapolate one from a screening or cessation trial.
Equity, capability, and distribution
Nominally identical coverage does not ensure equal ability to use it. A transport burden or a lost workday imposes different costs across households. Administrative rules can disproportionately affect people with limited language proficiency, digital access, disability accommodations, or access to primary care. The mammography cost-sharing findings show a greater screening response in lower-income and lower-education areas in the studied Medicare setting.
Rewards can compound these inequalities if their earning criteria ignore unequal access. A person who has a convenient clinic and reliable transport can earn the same fixed screening reward more readily than a person facing structural barriers. A premium discount linked to completion may consequently redistribute financial benefits by capacity as well as by behavior. Evaluation should report who becomes eligible, who receives the reward, whose care improves, and who bears residual costs.
Distributional evaluation can coexist with economic efficiency. Differences in subgroup take-up, clinical benefit, administrative burden, and out-of-pocket payments are measurable results. Their interpretation should be explicit rather than buried in aggregate rates. Transparent exceptions and accommodation procedures can also influence the incentive actually available to patients.
Measurement, Identification, and Validation
Causal estimands and treatment assignment
A causal statement specifies population, treatment assignment, actual exposure, comparison, endpoint, and follow-up. If a randomized experiment assigns an incentive offer, its directly identifiable intention-to-treat effect is the difference in average outcome between assigned groups. If only some offered the benefit receive it, the effect of receipt is a different estimand requiring assumptions. When assignment occurs by employer or plan sponsor, statistical uncertainty must reflect clustering at the assignment level.
The Oregon lottery illustrates this issue: random assignment provided an opportunity to obtain coverage rather than randomly controlling every aspect of individual insurance receipt. The assignment contrast is robust to many confounders, but translating it into an effect of coverage requires an instrumental-variable interpretation, including exclusion and compliance assumptions. The same caution applies when a patient is offered a screening reminder but does not read it.
Natural experiments demand scrutiny of parallel trends, anticipation, plan switching, coding revisions, and cointerventions. If a deductible exemption arrives at the same time as automatic screening outreach, a before–after increase cannot identify the isolated price effect. If an insurer changes enrollment eligibility, a difference in observed use can reflect patient composition. Event-study checks and competing comparison groups can reduce, but cannot automatically eliminate, these concerns.
Numerator, denominator, and data-source validity
A screening rate is a ratio. Its numerator requires a definition of valid completion and service dates; its denominator requires a population eligible under the same recommendation, with a defined interval and continuous enrollment as needed. Counting every member as eligible systematically distorts population rates. Changing age thresholds or test intervals changes rates even without a behavior change.
Claims data capture billed and paid episodes with details of code, provider, date, network, allowed amount, and cost sharing. They may omit public-program tests, free home tests, self-paid treatment, or care under a different insurer. Clinical records provide indications and results but may be fragmented across systems. Registries improve longitudinal completion measurement but vary in coverage. A reliable study combines these sources or explicitly measures resulting underascertainment.
For costs, billed charges, allowed amounts, insurer paid claims, household spending, and economic opportunity cost should be recorded separately. A reduction in claims after a deductible increase may partly move the financing burden to patients. A cross-country monetary comparison requires a reference price year, currency conversion or purchasing-power adjustment, and consistent service boundaries.
Endpoint validation and competing interpretations
An intervention intended to reduce mortality should ultimately be judged against valid mortality or morbidity evidence, subject to the available follow-up and study feasibility. Intermediate endpoints are useful but require justified links to patient-important outcomes. A lower positive-depression-screen rate in a trial is not a general effect on every psychiatric outcome; increased medication fills are not equivalent to a verified reduction in cardiovascular events.
The randomized Oregon clinical findings illustrate the importance of reporting significant and nonsignificant endpoints alongside confidence intervals. The MI FREEE primary endpoint illustrates the same principle: selected secondary improvements should be reported without reclassifying a nonsignificant primary composite as confirmed efficacy. These methodological qualifications are essential to a balanced scientific review.
A negative study of rewards should also preserve the baseline intervention. The mailed FIT incentive trial tested the marginal addition of modest rewards when participants were already sent a home test. It is not an experiment comparing all possible rewards with doing nothing. Likewise, an employee colonoscopy trial does not estimate the effect of the same reward in remote, resource-poor settings.
Heterogeneity, uncertainty, and transportability
Price response can differ with income, clinical risk, prior participation, geography, insurance continuity, provider availability, and the level of time burden. Clinical effectiveness can differ with disease prevalence and indication. Financial effects can differ with baseline price, treatment capacity, enrollment turnover, and the financing system. These moderators should be prespecified where data permit.
A cross-country rate is a description, not a causal estimate of insurance policy. The OECD cancer screening comparison uses national data subject to variations in target age group and measurement. Institutional differences in organized invitation systems, registries, provider supply, and diagnostic follow-up are essential to interpretation. One should not infer that a nation with a higher rate owes that difference to a more generous copayment exemption.
Economic sensitivity analyses should vary uptake, baseline event probability, relative intervention efficacy, false-positive rates, follow-up completion, program costs, time horizon, membership persistence, and discounting. Uncertainty ranges belong alongside expected values. Where the original evidence lacks a numerical estimate, no simulated parameter should be presented as a checked historical fact.
Sources and editorial verification
The evidence ledger accompanying this monograph records the exact external research URLs, bibliographic identity, and proposition each source is used to support. Legislation substantiates legal eligibility; agency guidance describes implementation; clinical recommendation methodology concerns net benefit; experiments support specified causal estimates; observation supports associations under its identification strategy; economic projections support model-based implications. Source selection and interpretation preserve those differences.
The full article text is written with short contextual hyperlinks at the propositions they support. References give full author-year bibliographic records and direct URLs. A link's presence alone does not verify its substantive fit; manual source-to-claim comparison remains part of scholarly review. Technical link counting is an additional, narrower test and should be reported as such.
The evidence base has limitations. The dossier does not undertake patient-level reanalysis, independent replication of randomized estimates, a new global screening meta-analysis, country-by-country legal compliance determinations, or external peer review. Some publisher full texts are paywalled, so direct metadata, abstracts, official summaries, and available source sections constrain verification. Uncertainty from such sources is disclosed rather than resolved by conjecture.
International Comparative Synthesis
Comparing financing and implementation systems
The United States organizes much preventive entitlement through recommended-service requirements imposed on many health plans, with substantial complexity around legal eligibility, network treatment, and billing classification. European organized screening emphasizes national public health program governance and quality-assured invitations under common policy guidance but diverse national implementation. Australia's screening programs illustrate public supply of tests and invitations as an alternative or complement to service-by-service insurance reimbursement.
These architectures alter different components of effective access. Zero cost sharing targets direct financial expense. Invitation and reminder systems target awareness and coordination. Home testing reduces travel and scheduling effort. Provider performance arrangements target offer and follow-up. A combined system can be more effective than its nominal price suggests, but the marginal causal contribution of each component must be measured.
The WHO universal coverage discussion adds the financing context: being entitled to a service and obtaining it without hardship are connected but distinct achievements. In a setting without reliable workforce, supplies, or diagnostics, a first-dollar benefit can have little practical effect. In a setting with abundant provision but substantial copayments, direct price reduction may be highly relevant.
Synthesis of principal empirical findings
The strongest general inference from the evidence is that demand for medical care responds to insurance prices, demonstrated by RAND and subsequent studies, but an elasticity measured for general care does not transfer unchanged to every preventive intervention. Broad insurance expansion can raise preventive use and financial protection, as Oregon demonstrates, without establishing a statistically significant short-horizon improvement in every physical indicator.
Targeted medication cost-sharing relief can increase adherence. In MI FREEE the primary cardiovascular composite remained statistically inconclusive while adherence and some secondary endpoints improved. The distinction is central to evaluation: uptake is observed within the treatment pathway, whereas clinical events require sufficient time, adherence, and statistical precision.
Financial rewards have high-certainty evidence for increased verified smoking cessation in the reviewed settings. Reward evidence for screening is more heterogeneous: a substantial colonoscopy reward produced a small absolute gain, while smaller lottery or cash incentives added to mailed FIT tests showed no significant improvement. The comparison establishes context dependence rather than a universal threshold reward.
Finally, the economics of prevention are multidimensional. The economic distinction between saving and value is essential: resource-saving prevention is one valuable case, but clinically beneficial prevention can raise expenditure while providing a favorable cost per health gain. A payer's short-term budget and society's long-term welfare should be analyzed transparently and separately.
Unresolved scientific problems
Important evidence gaps remain. Studies must better measure how much first-dollar eligibility becomes actual completed care when time and provider barriers persist. They must connect screening reward experiments to diagnostic completion and patient-important outcomes rather than initial test counts alone. They must measure how insurer switching changes private incentives to invest in benefits that yield health gains over a long horizon. They must distinguish induced new prevention from a shift of services across payers.
Distributive design requires empirical work on whether incentives disproportionately reward people with easier access, and whether tailored accommodations change this pattern. International comparison needs better harmonized measures of eligibility, invitation, follow-up, and service quality. Vaccine benefit evaluation requires product- and population-specific epidemiological and cost evidence. Each of these is a feasible research question grounded in existing methods; no new theory is asserted.
Integrated findings
The first finding is institutional. A preventive insurance benefit is effective only as delivered through an eligibility and care pathway. Coverage language, administrative classification, invitation, supply, and follow-up jointly determine whether a person receives clinically indicated care.
The second finding is causal. Service uptake, health outcome, household protection, insurer claims, and social cost are separate outcomes. The original experiments reviewed here demonstrate that changes in the first do not mechanically determine all others. The strength of evidence should follow the endpoint actually studied.
The third finding is economic. The same clinically useful intervention can have different financial consequences for a commercial insurer, a public payer, a household, and society because costs, risks, and benefits occur at different times and fall on different institutions. A cost-offset estimate is therefore incomplete until its perspective, comparator, and horizon are defined.
The fourth finding concerns heterogeneity. The value of a financial incentive depends on the baseline effective price, test burden, patient circumstances, clinical value, and provider organization. Randomized reward effects for smoking cessation and colorectal testing are consistent with this conclusion when their different interventions are preserved.
The fifth finding concerns fairness as an empirical dimension of design. Identical formal eligibility can coexist with unequal capacity to use services or earn contingent rewards. Distributional evidence belongs in the evaluation alongside aggregate participation, health outcomes, and financial totals.
Conclusion
Preventive care incentives and health insurance benefit design link clinical prevention to the contractual and institutional organization of health care. They influence whether an eligible person receives a recommended intervention, how clinicians provide and follow up the service, and how future health and expenditure are distributed across patients, insurers, providers, and public systems.
The primary empirical literature confirms that insurance prices and targeted rewards can influence behavior, while also documenting effects that are modest, heterogeneous, or statistically inconclusive. Randomized insurance and medication-coverage research establishes changes in use and adherence; screening trials show that the marginal value of a reward depends on the existing delivery arrangement; official screening guidance demonstrates the necessity of evidence-based selection and follow-up. These results warrant precise interpretation by population and outcome rather than a universal prediction of improved health or cost savings.
The economic conclusion follows from conventional welfare and budget-impact analysis. Beneficial prevention may save resources, may increase expenditure while improving health, or may produce harms when testing is poorly targeted or follow-up fails. Its value must be evaluated with separate clinical, household, insurer, and social measures. International program differences further demonstrate that nominal insurance coverage is only part of effective access.
The monograph's original contribution is a critical comparative synthesis connecting benefit eligibility, behavior, clinical evidence, insurance accounting, long-term outcomes, and distributive consequences under the same explicit analytical distinctions. It claims no new theory, independent clinical practice guideline, newly estimated treatment effect, or global cost-saving rate. The governing scholarly requirement is to preserve the exact intervention, counterfactual, population, outcome, uncertainty, and horizon for every important conclusion.
Technical Appendix: Empirical Evaluation Protocol
An evaluation of a proposed preventive-benefit arrangement should preregister the exact insurance setting and eligible population, including age, risk, existing care, enrollment continuity, and exclusions. It should distinguish offer, availability, actual receipt, and completion of follow-up.
The intervention must record the specific change in deductible, copayment, coinsurance, reward schedule, service invitation, provider payment, or administrative process. The comparator should include all usual outreach already present. Any concurrent benefit, screening recommendation, or billing-code change requires documentation.
Outcomes should be ordered as invitation and information receipt, actual service utilization, clinically appropriate completion, abnormal-result follow-up, treatment initiation, harms, patient-important health outcomes, household expenditure, payer expenditure, and social resource use. Each requires a denominator and follow-up period.
Randomized assignment should be analyzed with attention to unit of assignment and clustering. Studies interpreting receipt rather than assignment require assumptions about adherence and instrumental identification. Quasi-experimental estimates require a justified counterfactual trend and checks for selection, anticipation, and changes in coding or provider capacity.
Economic work should report direct program cost, incentive payouts to both marginal and inframarginal participants, administration cost, downstream treatment, discounting, membership exits, currency-year, and uncertainty. Observed outcomes and projected values must appear in distinct fields. Cost offsets, cost-effectiveness, and budget impact should be separately stated.
Validation should reconcile the clinical recommendation applicable at intervention time, the statutory or contractual entitlement, the actual service code, and source-specific numerical findings. Cross-jurisdiction comparison should test comparability of populations, delivery arrangements, and screening indicators before transporting treatment effects.
References
Baicker, Katherine, Sarah L. Taubman, Heidi L. Allen, Mira Bernstein, Jonathan H. Gruber, Joseph P. Newhouse, Eric C. Schneider, Bill J. Wright, Alan M. Zaslavsky, and Amy N. Finkelstein. 2013. “The Oregon Experiment—Effects of Medicaid on Clinical Outcomes.” New England Journal of Medicine 368 (18): 1713–1722. Source.
Baicker, Katherine, Sendhil Mullainathan, and Joshua Schwartzstein. 2015. “Behavioral Hazard in Health Insurance.” Quarterly Journal of Economics 130 (4): 1623–1667. Source.
Brot-Goldberg, Zarek C., Amitabh Chandra, Benjamin R. Handel, and Jonathan T. Kolstad. 2017. “What Does a Deductible Do? The Impact of Cost-Sharing on Health Care Prices, Quantities, and Spending Dynamics.” Quarterly Journal of Economics 132 (3): 1261–1318. Source.
Chernew, Michael E., Mayur R. Shah, Arnold Wegh, Stephen N. Rosenberg, Iver A. Juster, Allison B. Rosen, Michael C. Sokol, Kristina Yu-Isenberg, and A. Mark Fendrick. 2008. “Impact of Decreasing Copayments on Medication Adherence Within a Disease Management Environment.” Health Affairs 27 (1): 103–112. Source.
Choudhry, Niteesh K., Jerry Avorn, Robert J. Glynn, et al. 2011. “Full Coverage for Preventive Medications after Myocardial Infarction.” New England Journal of Medicine 365 (22): 2088–2097. Source.
Cohen, Joshua T., Peter J. Neumann, and Milton C. Weinstein. 2008. “Does Preventive Care Save Money? Health Economics and the Presidential Candidates.” New England Journal of Medicine 358 (7): 661–663. Source.
Council of the European Union. 2022. Council Recommendation of 9 December 2022 on Strengthening Prevention Through Early Detection: A New EU Approach on Cancer Screening. 2022/C 473/01. Official Journal C 473: 1–10. Source.
Finkelstein, Amy, Sarah Taubman, Bill Wright, Mira Bernstein, Jonathan Gruber, Joseph P. Newhouse, Heidi Allen, and Katherine Baicker. 2012. “The Oregon Health Insurance Experiment: Evidence from the First Year.” Quarterly Journal of Economics 127 (3): 1057–1106. Source.
Ito, Kouta, Jerry Avorn, William H. Shrank, Michele Toscano, Claire Spettel, Troyen Brennan, and Niteesh K. Choudhry. 2015. “Long-Term Cost-Effectiveness of Providing Full Coverage for Preventive Medications after Myocardial Infarction.” Circulation: Cardiovascular Quality and Outcomes 8 (3): 252–259. Source.
Maciosek, Michael V., Amy B. LaFrance, Steven P. Dehmer, Dana A. McGree, Thomas J. Flottemesch, Zack Xu, and Leif I. Solberg. 2017. “Updated Priorities Among Effective Clinical Preventive Services.” Annals of Family Medicine 15 (1): 14–22. Source.
Manning, Willard G., Joseph P. Newhouse, Naihua Duan, Emmett B. Keeler, Arleen Leibowitz, and M. Susan Marquis. 1987. “Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment.” American Economic Review 77 (3): 251–277. Source.
Mehta, Shivan J., Jordyn Feingold, Matthew Vandertuyn, Tess Niewood, Catherine Cox, Chyke A. Doubeni, Kevin G. Volpp, and David A. Asch. 2017. “Active Choice and Financial Incentives to Increase Rates of Screening Colonoscopy—A Randomized Controlled Trial.” Gastroenterology 153 (5): 1227–1229.e2. Source.
Mehta, Shivan J., Rebecca S. Pepe, Nicole B. Gabler, et al. 2019. “Effect of Financial Incentives on Patient Use of Mailed Colorectal Cancer Screening Tests: A Randomized Clinical Trial.” JAMA Network Open 2 (3): e191156. Source.
Notley, Caitlin, Sarah Gentry, Jonathan Livingstone-Banks, Linda Bauld, Rafael Perera, Mariana Conde, and Jamie Hartmann-Boyce. 2025. “Incentives for Smoking Cessation.” Cochrane Database of Systematic Reviews 2025 (1): CD004307. DOI 10.1002/14651858.CD004307.pub7. Source.
Organisation for Economic Co-operation and Development. 2025. Health at a Glance 2025: OECD Indicators. “Cancer Screening.” Paris: OECD Publishing. Source.
Services Australia. 2025. “Screening, Tests and Scans Covered by Medicare.” Australian Government. Source.
Supreme Court of the United States. 2025. Kennedy v. Braidwood Management, Inc., No. 24–316, decided June 27, 2025. Judicial opinion reproduced by Cornell Legal Information Institute. Source.
Trivedi, Amal N., William Rakowski, and John Z. Ayanian. 2008. “Effect of Cost Sharing on Screening Mammography in Medicare Health Plans.” New England Journal of Medicine 358 (4): 375–383. Source.
U.S. Departments of Labor, Health and Human Services, and the Treasury. 2013. “FAQs About Affordable Care Act Implementation (Part XII).” Centers for Medicare & Medicaid Services. Source.
U.S. Preventive Services Task Force. 2023, updated online. Procedure Manual, Section 6: Methods for Arriving at a Recommendation. Agency for Healthcare Research and Quality. Source.
United States Congress. 2010, as subsequently amended. Public Health Service Act § 2713, codified at 42 U.S.C. § 300gg–13, Coverage of Preventive Health Services. Office of the Law Revision Counsel. Source.
Volpp, Kevin G., Andrea B. Troxel, Mark V. Pauly, et al. 2009. “A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation.” New England Journal of Medicine 360 (7): 699–709. Source.
World Health Organization Regional Office for Europe. 2020. Screening Programmes: A Short Guide—Increase Effectiveness, Maximize Benefits and Minimize Harm. Copenhagen: WHO Regional Office for Europe. ISBN 978-92-890-5478-2. Source.
World Health Organization Regional Office for Europe. 2022. A Short Guide to Cancer Screening: Increase Effectiveness, Maximize Benefits and Minimize Harm. Copenhagen: WHO Regional Office for Europe. ISBN 978-92-890-5756-1. Source.
World Health Organization. 2025. “Universal Health Coverage (UHC).” Fact sheet, December 5, 2025. Source.